TY - JOUR T1 - Competitiveness in Turkey the Pharmaceutical Industry TT - Türkiye İlaç Sektöründe Rekabetin Ölçülmesi AU - Yıldırım, Hasan Hüseyin AU - Mestanoğlu, Melih PY - 2019 DA - October Y2 - 2019 DO - 10.21733/ibad.612571 JF - IBAD Sosyal Bilimler Dergisi JO - IBAD PB - Hayrullah KAHYA WT - DergiPark SN - 2687-2811 SP - 340 EP - 352 LA - en AB - One of the most basic needs of individuals, thepharmaceutical industry, which produces health-oriented products, has improvedsignificantly to improve the quality of life of individuals. Nowadays, thepharmaceutical industry is a global industry with high economic potential andwith high R & D costs. As in other industrial units of the economy, theintense competition environment is becoming more and more important for thepharmaceutical sector. In this study, domestic and foreign manufacturersoperating in Turkey are determined and it is aimed to determine the competitivecondition of the pharmaceutical industry with the obtained data from thecompanies. Also, a frequency analysis was carried out to generally evaluate theopinions of manufacturers and suppliers in the sector regarding the competitivesituation. T-test was conducted to determine whether there was a differencebetween two groups in terms of the competitive situation. As a result, astatistically significant difference was found between the manufacturers andthe suppliers. KW - Industry Analysis KW - Pharmaceutical Industry KW - Competitive Analysis KW - Survey Analysis KW - Turkey N2 - Thehealth-producing pharmaceutical sector, which meets one of the most basic needsof individuals, has developed at a significant level to improve the quality oflife for individuals. Today, the pharmaceutical industry is a global industrywith great economic potential and incurring high R & D costs. As in theother industrial units of the economy, a state of intense competition exists inthe pharmaceutical sector. In this study, domestic and foreign manufacturersoperating in Turkey are determined and it is aimed to determine the competitivecondition of the pharmaceutical industry with the obtained data from the companies.Also, a frequency analysis was carried out to generally evaluate the opinionsof manufacturers and suppliers in the sector regarding the competitivesituation. T-test was conducted to determine whether there was a differencebetween two groups in terms of the competitive situation. As a result, astatistically significant difference was found between the manufacturers andthe suppliers. CR - Adrian, T. and David, H. (1995). Industrial Policy and the Pharmaceutical Industry (London: Office of Health Economics) CR - Akbolat, M. and Işık, O. (2012). Hastanelerde Rekabet Stratejileri ve Performans. Atatürk Üniversitesi Sosyal Bilimler Enstitüsü Dergisi 2012 16 (1): 401-424 CR - Akın, C.S. (2007). Sağlık ve Sağlık Harcamalarının Ekonomik Büyüme Üzerine Etkisi: Türkiye’de Sağlık Sektörü Harcamaları. YYLT, Adana, Çukurova Üniversitesi, SBE. CR - Brand Finance, Pharma 10, The Annual Report On The Most Valuable and Strongest Pharma Brands, February 2019 CR - Doğan, İ.F., Bakan, İ. and Hayva, S. (2017). Sağlık Sektörünün Temel Aktörleri Olan Hastanelerde Rekabet Stratejilerinin Kaliteye Etkisi CR - Forbes (2017) The World’s Biggest Public Companies, https://www.forbes.com/global 2000/list/#industry: Pharmaceuticals date accessed: 08/04/2018 CR - İlaç Endüstrisi İşverenler Sendikası (İEİS), 2016 http://www.ieis.org.tr/ieis/tr/indicators/ 32/dunya-ilac-pazari, date accessed: 09/04/2018 CR - İlaç Endüstrisi İşverenler Sendikası (İEİS), 2017 January – March, Türkiye İlaç Pazarı, p.2 CR - ISO (2016), ISO İlk ve İkinci 500 Sanayi Kuruluşları, http://www.iso500.org.tr/, date accessed: 12/04/2018 CR - Karakoç, H.D. (2005). İlaç Sektöründe Fiyat Rekabeti. Rekabet Kurumu, Ankara. CR - Kaynak, S. (2016). Türk İlaç Sektörünün Rekabet Yapısı ve Yoğunlaşma Analizi. Ondokuz Mayıs Üniversitesi İktisadi ve İdari Bilimler Fakültesi CR - KPMG, 2018. Sektörel Bakış – İlaç, date accessed: 10/04/2018 CR - Levy, R. (1999), The Pharmaceutical Industry. A Discussion of Competitive and Antirust Issues in an Environment of Change, March, 1999 CR - OECD (2003). Regulatory Reform Review of Germany (DAFFE/COMP/WP2(2003)7). Working Party No. 2 on Competition and Regulation, Review of Germany. CR - Sarsın Kaya, D. (2016). İlaç Sektörü, January 2016, p.9, 16, 17 CR - Scherer, F.M. and D. Ross (1990) Industrial Market Structure and Economic Performance, Houghton Mifflin Co., Boston CR - Trade Map, https://www.trademap.org/ date accessed: 08/04/2018 CR - Turkish Republic, Department of Science and Industry (2015). Strateji Belgesi ve Eylem Planı: Türkiye İlaç Sektörü. 2015-2018, p.9 CR - Turkish Republic, Department of Science and Industry (2016). Sektörel Rapor ve Analizler: İlaç Sektörü raporu, p.8, 14 CR - W. Roberts, P. (1999), Product Innovation, Product- Market Competition and Persistent Profitability in the U.S. Pharmaceutical Industry UR - https://doi.org/10.21733/ibad.612571 L1 - https://dergipark.org.tr/en/download/article-file/855811 ER -